Microwave ablation of primary breast cancer inhibits metastatic progression in model mice via activation of natural killer cells.
NK cells
breast cancer
metastasis
microwave ablation
surgery
Journal
Cellular & molecular immunology
ISSN: 2042-0226
Titre abrégé: Cell Mol Immunol
Pays: China
ID NLM: 101242872
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
04
03
2020
accepted:
14
04
2020
pubmed:
10
5
2020
medline:
1
4
2022
entrez:
10
5
2020
Statut:
ppublish
Résumé
Surgery is essential for controlling the symptoms and complications of stage IV breast cancer. However, locoregional treatment of primary tumors often results in distant progression, including lung metastasis, the most common type of visceral metastasis. As a minimally invasive thermal therapy, microwave ablation (MWA) has been attempted in the treatment of breast cancer, but the innate immune response after MWA has not yet been reported. Using two murine models of stage IV breast cancer, we found that MWA of primary breast cancer inhibited the progression of lung metastasis and improved survival. NK cells were activated after MWA of the primary tumor and exhibited enhanced cytotoxic functions, and the cytotoxic pathways of NK cells were activated. Depletion experiments showed that NK cells but not CD4+ or CD8+ T cells played a pivotal role in prolonging survival. Then, we found that compared with surgery or control treatment, MWA of the primary tumor induced completely different NK-cell-related cytokine profiles. Macrophages were activated after MWA of the primary tumor and produced IL-15 that activated NK cells to inhibit the progression of metastasis. In addition, MWA of human breast cancer stimulated an autologous NK-cell response. These results demonstrate that MWA of the primary tumor in metastatic breast cancer inhibits metastatic progression via the macrophage/IL-15/NK-cell axis. MWA of the primary tumor may be a promising treatment strategy for de novo stage IV breast cancer, although further substantiation is essential for clinical testing.
Identifiants
pubmed: 32385362
doi: 10.1038/s41423-020-0449-0
pii: 10.1038/s41423-020-0449-0
pmc: PMC8429677
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2153-2164Subventions
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 81771953
Informations de copyright
© 2020. CSI and USTC.
Références
Harris, E., Barry, M. & Kell, M. R. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann. Surg. Oncol. 20, 2828–2834 (2013).
doi: 10.1245/s10434-013-2998-2
pubmed: 23653043
Bafford, A. C. et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 115, 7–12 (2009).
doi: 10.1007/s10549-008-0101-7
pubmed: 18581232
Soran A. et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 25, 3141–3149 (2018).
doi: 10.1245/s10434-018-6494-6
pubmed: 29777404
Badwe, R. et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 16, 1380–1388 (2015).
doi: 10.1016/S1470-2045(15)00135-7
pubmed: 26363985
Gunduz, N., Fisher, B. & Saffer, E. A. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 39, 3861–3865 (1979).
pubmed: 476622
Fisher, B., Gunduz, N., Coyle, J., Rudock, C. & Saffer, E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 49, 1996–2001 (1989).
pubmed: 2702641
Demicheli, R., Retsky, M. W., Swartzendruber, D. E. & Bonadonna, G. Proposal for a new model of breast cancer metastatic development. Ann. Oncol. 8, 1075–1080 (1997).
doi: 10.1023/A:1008263116022
pubmed: 9426326
Al-Sahaf, O., Wang, J. H., Browne, T. J., Cotter, T. G. & Redmond, H. P. Surgical injury enhances the expression of genes that mediate breast cancer metastasis to the lung. Ann. Surg. 252, 1037–1043 (2010).
doi: 10.1097/SLA.0b013e3181efc635
pubmed: 21107114
Krall J. A. et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci Transl Med. 10, eaan3464 (2018).
pubmed: 29643230
pmcid: 6364295
doi: 10.1126/scitranslmed.aan3464
Coffey, J. C. et al. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 4, 760–768 (2003).
doi: 10.1016/S1470-2045(03)01282-8
pubmed: 14662433
O’Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997).
doi: 10.1016/S0092-8674(00)81848-6
pubmed: 9008168
Maniwa, Y., Kanki, M. & Okita, Y. Importance of the control of lung recurrence soon after surgery of pulmonary metastases. Am. J. Surg. 179, 122–125 (2000).
doi: 10.1016/S0002-9610(00)00244-0
pubmed: 10773147
Lange, P. H., Hekmat, K., Bosl, G., Kennedy, B. J. & Fraley, E. E. Acclerated growth of testicular cancer after cytoreductive surgery. Cancer 45, 1498–1506 (1980).
doi: 10.1002/1097-0142(19800315)45:6<1498::AID-CNCR2820450633>3.0.CO;2-7
pubmed: 6153570
Dromi, S. A. et al. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology 251, 58–66 (2009).
pubmed: 19251937
pmcid: 2663580
doi: 10.1148/radiol.2511072175
Zerbini, A. et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 138, 1931–1942 (2010).
doi: 10.1053/j.gastro.2009.12.051
pubmed: 20060829
Zerbini, A. et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 66, 1139–1146 (2006).
doi: 10.1158/0008-5472.CAN-05-2244
pubmed: 16424051
Behm, B. et al. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. Gut 65, 134–143 (2016).
doi: 10.1136/gutjnl-2014-308286
pubmed: 25524262
Chu, K. F. & Dupuy, D. E. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat. Rev. Cancer 14, 199–208 (2014).
doi: 10.1038/nrc3672
pubmed: 24561446
Xu, A. et al. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis. Cell Mol. Immunol. 16, 820–832 (2019).
doi: 10.1038/s41423-018-0184-y
pubmed: 30467420
Sanchez-Ortiz, R. F., Tannir, N., Ahrar, K. & Wood, C. G. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J. Urol. 170, 178–179 (2003).
doi: 10.1097/01.ju.0000070823.38336.7b
pubmed: 12796677
Kim, H., Park, B. K. & Kim, C. K. Spontaneous regression of pulmonary and adrenal metastases following percutaneous radiofrequency ablation of a recurrent renal cell carcinoma. Korean J. Radiol. 9, 470–472 (2008).
pubmed: 18838859
pmcid: 2627212
doi: 10.3348/kjr.2008.9.5.470
Soanes, W. A., Ablin, R. J. & Gonder, M. J. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J. Urol. 104, 154–159 (1970).
doi: 10.1016/S0022-5347(17)61690-2
pubmed: 4987666
Zhou, W. et al. US-guided percutaneous microwave coagulation of small breast cancers: a clinical study. Radiology 263, 364–373 (2012).
doi: 10.1148/radiol.12111901
pubmed: 22438362
Burak, W. E. Jr et al. Radiofrequency ablation of invasive breast carcinoma followed by delayed surgical excision. Cancer 98, 1369–1376 (2003).
doi: 10.1002/cncr.11642
pubmed: 14508822
Manenti, G. et al. Small breast cancers: in vivo percutaneous US-guided radiofrequency ablation with dedicated cool-tip radiofrequency system. Radiology 251, 339–346 (2009).
doi: 10.1148/radiol.2512080905
pubmed: 19304918
Palussiere, J. et al. Radiofrequency ablation as a substitute for surgery in elderly patients with nonresected breast cancer: pilot study with long-term outcomes. Radiology 264, 597–605 (2012).
doi: 10.1148/radiol.12111303
pubmed: 22692040
Roubidoux, M. A. et al. Small (< 2.0-cm) breast cancers: mammographic and US findings at US-guided cryoablation–initial experience. Radiology 233, 857–867 (2004).
doi: 10.1148/radiol.2333031734
pubmed: 15567802
Simon, C. J., Dupuy, D. E. & Mayo-Smith, W. W. Microwave ablation: principles and applications. Radiographics 25(Suppl 1), S69–S83 (2005).
doi: 10.1148/rg.25si055501
pubmed: 16227498
Zhou, W. et al. Comparison of ablation zones among different tissues using 2450-MHz cooled-shaft microwave antenna: results in ex vivo porcine models. PLoS ONE 8, e71873 (2013).
pubmed: 23951262
pmcid: 3741232
doi: 10.1371/journal.pone.0071873
Zhou, W. et al. Image and pathological changes after microwave ablation of breast cancer: a pilot study. Eur. J. Radiol. 83, 1771–1777 (2014).
doi: 10.1016/j.ejrad.2014.06.015
pubmed: 25043496
Li, L. et al. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer. J. Transl. Med. 15, 23 (2017).
pubmed: 28137271
pmcid: 5282633
doi: 10.1186/s12967-017-1124-9
Zhu, J. et al. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: a pre-clinical study in a murine model. Diagn. Inter. Imaging 99, 135–142 (2018).
doi: 10.1016/j.diii.2017.12.011
Todorova, V. K., Klimberg, V. S., Hennings, L., Kieber-Emmons, T. & Pashov, A. Immunomodulatory effects of radiofrequency ablation in a breast cancer model. Immunol. Investig. 39, 74–92 (2010).
doi: 10.3109/08820130903428291
Danna, E. A. et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 64, 2205–2211 (2004).
doi: 10.1158/0008-5472.CAN-03-2646
pubmed: 15026364
Pulaski, B. A. & Ostrand-Rosenberg, S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58, 1486–1493 (1998).
pubmed: 9537252
Habif, G., Crinier, A., Andre, P., Vivier, E. & Narni-Mancinelli, E. Targeting natural killer cells in solid tumors. Cell Mol. Immunol. 16, 415–422 (2019).
pubmed: 30911118
pmcid: 6474204
doi: 10.1038/s41423-019-0224-2
Sivori, S. et al. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol. Immunol. 16, 430–441 (2019).
pubmed: 30778167
pmcid: 6474200
doi: 10.1038/s41423-019-0206-4
Banh, C., Miah, S. M., Kerr, W. G. & Brossay, L. Mouse natural killer cell development and maturation are differentially regulated by SHIP-1. Blood 120, 4583–4590 (2012).
pubmed: 23034281
pmcid: 3512235
doi: 10.1182/blood-2012-04-425009
Young, H. A. & Ortaldo, J. Cytokines as critical co-stimulatory molecules in modulating the immune response of natural killer cells. Cell Res. 16, 20–24 (2006).
doi: 10.1038/sj.cr.7310004
pubmed: 16467872
Steel, J. C., Waldmann, T. A. & Morris, J. C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharm. Sci. 33, 35–41 (2012).
doi: 10.1016/j.tips.2011.09.004
pubmed: 22032984
Gerratana, L. et al. Pattern of metastasis and outcome in patients with breast cancer. Clin. Exp. Metastasis 32, 125–133 (2015).
doi: 10.1007/s10585-015-9697-2
pubmed: 25630269
Gu, Y., Wu, G., Zou, X., Huang, P. & Yi, L. Prognostic value of site-specific metastases and surgery in de novo stage IV triple-negative breast cancer: a population-based analysis. Med. Sci. Monit. 26, e920432 (2020).
pubmed: 32043484
pmcid: 7034402
Kassam, F. et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin. Breast Cancer 9, 29–33 (2009).
doi: 10.3816/CBC.2009.n.005
pubmed: 19299237
Pulaski B. A., Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. Chapter 20, Unit 20.2 (2001).
Ahmad, F. et al. Changes in interleukin-1beta and 6 after hepatic microwave tissue ablation compared with radiofrequency, cryotherapy and surgical resections. Am. J. Surg. 200, 500–506 (2010).
doi: 10.1016/j.amjsurg.2009.12.025
pubmed: 20887844
Dong, B. W. et al. Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma. Int. J. Hyperth. 19, 119–133 (2003).
doi: 10.1080/0265673021000017154
Jansen, M. C. et al. Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery 147, 686–695 (2010).
doi: 10.1016/j.surg.2009.10.053
pubmed: 20042207
Chapman, W. C. et al. Hepatic cryoablation, but not radiofrequency ablation, results in lung inflammation. Ann. Surg. 231, 752–761 (2000).
pubmed: 10767797
pmcid: 1421063
doi: 10.1097/00000658-200005000-00016
Rashid, O. M. et al. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery 153, 771–778 (2013).
doi: 10.1016/j.surg.2013.02.002
pubmed: 23489938
Vivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer cells. Nat. Immunol. 9, 503–510 (2008).
doi: 10.1038/ni1582
pubmed: 18425107
Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249–1255 (1999).
doi: 10.1038/15200
pubmed: 10545990
Sauter, B. et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423–434 (2000).
pubmed: 10662788
pmcid: 2195816
doi: 10.1084/jem.191.3.423
Walzer, T., Dalod, M., Robbins, S. H., Zitvogel, L. & Vivier, E. Natural-killer cells and dendritic cells: “l’union fait la force”. Blood 106, 2252–2258 (2005).
doi: 10.1182/blood-2005-03-1154
pubmed: 15933055
Chavez, M. et al. Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. Theranostics 8, 3611–3628 (2018).
pubmed: 30026870
pmcid: 6037035
doi: 10.7150/thno.25613
Kiniwa, T. et al. NK cells activated by Interleukin-4 in cooperation with Interleukin-15 exhibit distinctive characteristics. Proc. Natl Acad. Sci. USA 113, 10139–10144 (2016).
pubmed: 27551096
pmcid: 5018748
doi: 10.1073/pnas.1600112113
Zhang, M. et al. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc. Natl Acad. Sci. USA 115, E10915–E10924 (2018).
pubmed: 30373815
pmcid: 6243244
Yoshimoto, T. et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J. Immunol. 161, 3400–3407 (1998).
pubmed: 9759857
Malek, T. R., Yu, A., Scibelli, P., Lichtenheld, M. G. & Codias, E. K. Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. J. Immunol. 166, 1675–1683 (2001).
doi: 10.4049/jimmunol.166.3.1675
pubmed: 11160210